Therapeutic Advances in Urology

“Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in mice with locally advanced or metastatic prostate cancer”¹

1.
Lebret T, Rouanne M, Hublarov O, et al. Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in mice with locally advanced or metastatic prostate cancer. Therapeutic Advances in Urology. Published online March 17, 2015:125-134. doi:10.1177/1756287215577329

Dr. Oleg Hublarov MD Triptorelin
Biographical Info Consultant Urological Surgeon at the Capital Clinic Riga with over 30 years’ experience in urology.
Oleg Hublarov has a MD from the Riga Medical School. Dr. Oleg Hublarov MD currently works at the Klinika LUC and has 2 years experience in researching Erectile dysfunction surgical management at the Clinic of Aesthetic Medicine of Medical Doctor Edward Yurshevich. One of their notable works include "Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancer". Published online May 17, 2015. doi:https://doi.org/10.1177/1756287215577329 [PubMed]
Pubmed | CapitalClinicRiga | Linkedin

Estimated Reading Time: < 1 min read

Related Posts